Share Email Print

Proceedings Paper

Laser light induced modulations in metabolic activities in human brain cancer
Author(s): Darrell B. Tata; Ronald W. Waynant
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

The role of low visible or near infra-red laser intensity in suppressing metabolic activity of malignant human brain cancer (glioblastoma) cells was investigated through the application of either a continuous wave 633nm HeNe or a pulsed picosecond 1,552nm wavelength laser. Human glioblastomas were exposed in their growth culture medium with serum for several energy doses. For both types of laser exposures the glioblastomas exhibited a maximal decline in the metabolic activity relative to their respective sham control counterparts at 10 J/cm2. The cellular metabolic activities for various treatment doses were measured through the colorimetric MTS metabolic assay after the laser exposure. Interestingly, addition of (the enzyme) catalase in the growth medium prior to the laser exposure was found to diminish the laser induced metabolic suppression for all fluence treatment conditions, thus suggesting a functional role of H2O2 in the metabolic suppression. Taken together, our findings reveal that visible or near infra-red low level light exposures could potentially be a viable tool in reducing the metabolic activity of cancers; evidence at hand implicates a role of light induced H2O2 in bringing about in part, suppression in the metabolic activity. Due to the cellular "biphasic" response to the laser exposure, further research needs to be undertaken to determine exposure parameters which would optimize metabolic and cellular growth suppression in-vivo.

Paper Details

Date Published: 12 February 2008
PDF: 12 pages
Proc. SPIE 6846, Mechanisms for Low-Light Therapy III, 684607 (12 February 2008); doi: 10.1117/12.763526
Show Author Affiliations
Darrell B. Tata, U.S. Food and Drug Administration (United States)
Ronald W. Waynant, U.S. Food and Drug Administration (United States)

Published in SPIE Proceedings Vol. 6846:
Mechanisms for Low-Light Therapy III
Michael R. Hamblin; Ronald W. Waynant; Juanita Anders, Editor(s)

© SPIE. Terms of Use
Back to Top